GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00062686
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
- Conditions
- Peritoneal CancerOvarian CancerNeoplasms, OvarianFallopian Tube Cancer
- First Posted Date
- 2003-05-28
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00061308
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 501
- Registration Number
- NCT00060931
- Locations
- 🇺🇸
GSK Investigational Site, Springfield, Virginia, United States
Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1210
- Registration Number
- NCT00060918
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- Biological: Immunotherapeutic SB719125 (Primary)
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT00058526
- Locations
- 🇮🇹
GSK Investigational Site, Perugia, Umbria, Italy
HerpeVac Trial for Young Women
- Conditions
- Herpes Simplex Infection
- Interventions
- Biological: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccineBiological: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8323
- Registration Number
- NCT00057330
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
- Conditions
- Major Depressive Disorder (MDD)
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 546
- Registration Number
- NCT00057239
- Locations
- 🇺🇸
GSK Investigational Site, Brown Deer, Wisconsin, United States
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 365
- Registration Number
- NCT00057226
- Locations
- 🇺🇸
GSK Investigational Site, Bellevue, Washington, United States
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 367
- Registration Number
- NCT00057213
- Locations
- 🇺🇸
GSK Investigational Site, Salt Lake City, Utah, United States
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
- First Posted Date
- 2003-03-13
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8231
- Registration Number
- NCT00056407
- Locations
GSK Investigational Site